Systematic review with meta-analysis

the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus

M. H. Hyun, Young-Sun Lee, Ji Hoon Kim, J. H. Je, Y. J. Yoo, Jong Eun Yeon, Kwan Soo Byun

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Background: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis. Aims: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus. Methods: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016. Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included. Results: Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% (odds ratio=0.23, 95% confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I2=0%). In the case series analysis (134 pregnancies), only two cases (1.5%) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring. Conclusions: For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.

Original languageEnglish
Pages (from-to)1493-1505
Number of pages13
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number12
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Tenofovir
Hepatitis B virus
Meta-Analysis
Mothers
Safety
Chronic Hepatitis B
Third Pregnancy Trimester
Second Pregnancy Trimester
Viral Load
Pregnancy
Hepatitis B Vaccines
Fetal Death

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{56594d823b874c5db397a9cd1693a550,
title = "Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus",
abstract = "Background: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis. Aims: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus. Methods: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016. Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included. Results: Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77{\%} (odds ratio=0.23, 95{\%} confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I2=0{\%}). In the case series analysis (134 pregnancies), only two cases (1.5{\%}) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring. Conclusions: For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.",
author = "Hyun, {M. H.} and Young-Sun Lee and Kim, {Ji Hoon} and Je, {J. H.} and Yoo, {Y. J.} and Yeon, {Jong Eun} and Byun, {Kwan Soo}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/apt.14068",
language = "English",
volume = "45",
pages = "1493--1505",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Systematic review with meta-analysis

T2 - the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus

AU - Hyun, M. H.

AU - Lee, Young-Sun

AU - Kim, Ji Hoon

AU - Je, J. H.

AU - Yoo, Y. J.

AU - Yeon, Jong Eun

AU - Byun, Kwan Soo

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis. Aims: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus. Methods: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016. Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included. Results: Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% (odds ratio=0.23, 95% confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I2=0%). In the case series analysis (134 pregnancies), only two cases (1.5%) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring. Conclusions: For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.

AB - Background: Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis. Aims: To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus. Methods: PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016. Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included. Results: Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% (odds ratio=0.23, 95% confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I2=0%). In the case series analysis (134 pregnancies), only two cases (1.5%) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring. Conclusions: For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.

UR - http://www.scopus.com/inward/record.url?scp=85018852826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018852826&partnerID=8YFLogxK

U2 - 10.1111/apt.14068

DO - 10.1111/apt.14068

M3 - Review article

VL - 45

SP - 1493

EP - 1505

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 12

ER -